Sotigalimab  (Synonyms: APX005M)

Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma^[1][2].

Sotigalimab (0-100 nM, 48 h) increases the expression of immune co-stimulatory molecules CD86 and MHC II; thereby increasing the expression of HLA-DR in human primary B cells^[3].
Sotigalimab (0-100 nM, 5 days) promote T cell responses, stimulates the T cell proliferation and IFN-γ secretion^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sotigalimab (0.3-30 mg/kg, iv, once weekly for 4 weeks) reduces the number of peripheral B lymphocytes without adverse effects on other organ systems in cynomolgus monkeys^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

144540.00

2305607-45-6

Liquid

Colorless to light yellow

[Sotigalimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Mark H O'Hara, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 Jan;22(1)  [Content Brief]

  [2]. Weiss SA, et al. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clin Cancer Res. 2024 Jan 5;30(1):74-81.  [Content Brief]

  [3]. Filbert EL, et al., APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol Immunother. 2021 Jul;70(7):1853-1865.  [Content Brief]